Compare LINK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | TCRX |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 57.9M |
| IPO Year | 2007 | 2021 |
| Metric | LINK | TCRX |
|---|---|---|
| Price | $3.29 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $8.67 | $8.50 |
| AVG Volume (30 Days) | 28.2K | ★ 443.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,679,000.00 | $2,816,000.00 |
| Revenue This Year | $8.30 | $286.83 |
| Revenue Next Year | $34.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.76 | $0.88 |
| 52 Week High | $15.15 | $2.57 |
| Indicator | LINK | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 50.53 |
| Support Level | $2.76 | $0.90 |
| Resistance Level | $4.11 | $1.23 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 29.52 | 59.00 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.